NeuroOne Medical Technologies Corporation
NMTC Healthcare Medical Devices
In the quarter to June 2026, revenue grew 16.3%, EPS fell 27.8% and free cash flow grew 26.9%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow NMTC
NeuroOne Medical Technologies Corporation (NMTC) EV/Sales
As of 16 October 2026, NeuroOne Medical Technologies Corporation (NMTC) trades at a EV/Sales of 0.7×. Over the past ten years it has ranged from −22.9× (May 2022) to 192× (August 2022); the current reading is higher than 20% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.4× | (66.82%) |
| FY2024 | 7.3× | 114.25% |
| FY2023 | 3.4× | (54.88%) |
| FY2022 | 7.5× | (94.85%) |
| FY2021 | 146× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.6× | (35.83%) |
| Mar 2026 | 4.0× | 0.64% |
| Dec 2025 | 4.0× | 65.06% |
| Sep 2025 | 2.4× | (7.08%) |
| 20 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AEMD Aethlon Medical, Inc. compare | −2.8× |
| TNON Tenon Medical, Inc. compare | −0.1× |
| RBOT Vicarious Surgical Inc. compare | n/m |
| NMTC NeuroOne Medical Technologies Corporation | 0.7× |
| CTSO Cytosorbents Corporation compare | 0.7× |
| BMRA Biomerica, Inc. compare | 0.9× |
| BTCY Biotricity Inc. compare | 1.7× |
| SINT SINTX TECHNOLOGIES, INC. compare | 3.7× |
| PETV PetVivo Holdings, Inc. compare | 23.4× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)